On December 13, 2019, Joe Thomas, a Class II member of the Board of Directors of Outlook Therapeutics, Inc., and a member of the Board’s Audit Committee, resigned his position as a director of the Company and all Board committees upon which he served, with immediate effect. Mr. Thomas’s resignation was not due to any disagreement with the Board or the Company. On December 18, 2019, the Board appointed current Class I director, Yezan Haddadin, to fill the vacancy on the Audit Committee and reduced the Board size from six directors to five directors to eliminate the vacancy created by Mr. Thomas’s resignation.